NASDAQ:SGMO - Sangamo Therapeutics Stock Price, Forecast & News

Sangamo Therapeutics trades on the NASDAQ under the ticker symbol "SGMO."

Sangamo Therapeutics Inc (NASDAQ:SGMO) posted its earnings results on Wednesday, November, 6th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.34) by $0.10. The biopharmaceutical company earned $21.96 million during the quarter, compared to analysts' expectations of $12.16 million. Sangamo Therapeutics had a negative return on equity of 30.33% and a negative net margin of 159.12%. The company's revenue was down 6.8% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.13) earnings per share. View Sangamo Therapeutics' Earnings History.

Sangamo Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Sangamo Therapeutics.

3 analysts have issued 12 month price targets for Sangamo Therapeutics' shares. Their forecasts range from $11.00 to $16.00. On average, they expect Sangamo Therapeutics' share price to reach $13.50 in the next year. This suggests a possible upside of 61.3% from the stock's current price. View Analyst Price Targets for Sangamo Therapeutics.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sangamo Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Sangamo Therapeutics.

Headlines about SGMO stock have trended somewhat negative recently, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Sangamo Therapeutics earned a news impact score of -1.0 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Sangamo Therapeutics.

Some companies that are related to Sangamo Therapeutics include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Sangamo Therapeutics investors own include NVIDIA (NVDA), Brainstorm Cell Therapeutics (BCLI), Advanced Micro Devices (AMD), Micron Technology (MU), Novavax (NVAX), Crispr Therapeutics (CRSP), Alibaba Group (BABA), Zuora (ZUO), Editas Medicine (EDIT) and Netflix (NFLX).

Sangamo Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Rhenman & Partners Asset Management AB (0.60%), Tocqueville Asset Management L.P. (0.12%), Alpine Global Management LLC (0.03%) and McGuire Investment Group LLC (0.02%). Company insiders that own Sangamo Therapeutics stock include Curt A Herberts III, Edward R Conner, H Stewart Parker, Kathy Yi, Saira Ramasastry and Steven J Mento. View Institutional Ownership Trends for Sangamo Therapeutics.

SGMO stock was sold by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB. View Insider Buying and Selling for Sangamo Therapeutics.

SGMO stock was acquired by a variety of institutional investors in the last quarter, including Tocqueville Asset Management L.P., Alpine Global Management LLC and McGuire Investment Group LLC. View Insider Buying and Selling for Sangamo Therapeutics.

Shares of SGMO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of SGMO stock can currently be purchased for approximately $8.37.

Sangamo Therapeutics has a market capitalization of $970.40 million and generates $84.45 million in revenue each year. The biopharmaceutical company earns $-68,330,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis. Sangamo Therapeutics employs 302 workers across the globe.View Additional Information About Sangamo Therapeutics.

The official website for Sangamo Therapeutics is http://www.sangamo.com/.

Sangamo Therapeutics' mailing address is 501 CANAL BLVD, RICHMOND CA, 94804. The biopharmaceutical company can be reached via phone at 510-970-6000 or via email at [email protected]